Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Fraternity removes member for ‘racist actions’ at Ole MissDR MAX PEMBERTON: We need more female doctors in the NHS... but there is a downside76ers president Daryl Morey has big plans to build NBA title team around Embiid and MaxeyChina's trade with other BRICS members up 11.3 pct in Q1Bank holiday boozeTwo suspects arrested in fatal shooting on Delaware college campus are not students, police sayThe number of fish on US overfishing list reaches an allTwo suspects arrested in fatal shooting on Delaware college campus are not students, police sayDodgers place Kelly on injured list. Buehler activated to make first start in 2 yearsDonald Trump calls Joe Biden weak on antisemitism, ignoring his own rhetoric
2.6328s , 6501.515625 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Global Gazetteer news portal